RxDoctor Payments Data

Alex Horchak, MD

Urology · Dubuque, IANPI 1033158209

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,680 of the $8,274 with a category attached, or 68.6%. It is spread thinly across 20 manufacturers, the largest accounting for just 19.6%. Reporting peaked in 2019 at $2,217 and has fallen 75.7% since, to $539 in 2025.

$8,274in general payments, 2019–2025

Across 284 payments — averaging $29.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neotract Inc.$2K
  • Axonics, Inc.$2K
  • Astellas Pharma US Inc$933
  • Pfizer$828
  • Coloplast$778
  • Boston Scientific$699
  • plus $2K from 14 others

What the payments were for

  • Travel & lodging$2,15226%
  • Food & beverage$5,68069%
  • Education$4425%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,274 in reported general payments places this provider in the 80th percentile of 114 urology providers in Iowa.

See all urology providers in Iowa

Medicare billing

Part B allowed, 2024
$152,370
Medicare patients
498
Services billed
1,729

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide30$427,907
XtandiEnzalutamide28$387,566
MyrbetriqMirabegron349$214,683
OrgovyxRelugolix45$121,648
GemtesaVibegron44$24,020
Tamsulosin Hcl856$20,358
Oxybutynin Chloride ErOxybutynin Chloride251$6,396
Alfuzosin Hcl ErAlfuzosin Hcl274$6,254
Finasteride373$5,583
Fesoterodine Fumarate ErFesoterodine Fumarate40$3,732
Mirabegron ErMirabegron12$3,693
Silodosin51$3,162
Dutasteride34$2,222
Solifenacin Succinate75$1,923
Tolterodine Tartrate ErTolterodine Tartrate29$1,668

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$933$602,249377 claims
Johnson & JohnsonErleada$652$427,90730 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$64$145,66889 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 114 urology providers in Iowa.

Other urology in Dubuque

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →